Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

NCT04551131 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Hemophagocytic Lymphohistiocytosis

Interventions

DRUG: Ruxolitinib
DRUG: Dexamethasone
DRUG: Etoposide

Sponsor

St. Jude Children's Research Hospital

Collaborators

Incyte Corporation
North American Consortium for Histiocytosis
Cures Within Reach